Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of Dry Powder Amikacin in DSTB
NCT04249531Phase 1Unknown
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2020
- Primary completion
- Apr 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amikacin liposome inhalation suspension in Tuberculosis (TB), sponsored by University Medical Center Groningen. Primary endpoints: Actual Dose Delivered at 1 day, Area Under the Curve 0-24h at 1 day and 3 more. Status: unknown.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04249531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249531.